Larvol ClinicEnasidenib Shows Greater Survival Benefit in IDH2-R172 Variant Patients with Relapsed/Refractory…Abstract19h ago19h ago
Larvol ClinicAbstractBackground: Neoadjuvant therapy (NT) is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), and yet reasons for…19h ago19h ago
Larvol ClinicAbstractPARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2…19h ago19h ago
Larvol ClinicAbstractIn newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care…19h ago19h ago
Larvol ClinicSequential Dosing of Sacituzumab Govitecan and Talazoparib in Metastatic TNBC: A Feasible StrategyPurpose: The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor (TOP1i) SN-38, coupled…20h ago20h ago
Larvol ClinicThe purpose of this study is to find out what effects, good and or bad STA-9090 has on colorectal…Cancer is a disease of uncontrolled growth. This growth is controlled in part by a series of proteins that are part of a growth pathway…3d ago3d ago
Larvol ClinicPhase II Trial of Short-Course Radiotherapy Combined with CAPOX and Camrelizumab Followed by…Background:Chemoradiotherapy followed by radical surgery is standard treatment for patients with locally advanced rectal cancer (LARC)…4d ago4d ago
Larvol ClinicBackground: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired…Methods:This Phase II, multicenter, single-arm, open-label study will assess preliminary safety and tolerability, antitumor activity, and…4d ago4d ago
Larvol ClinicComparing Symptom Monitoring Approaches for Ambulatory Cancer Surgery Patients: A Randomized…Background:An increasing proportion of cancer surgeries are ambulatory (≤ 1 day in hospital) procedures. Providing patients and their…4d ago4d ago
Larvol ClinicPhase I Trial of CCL21-Modified Dendritic Cells and Pembrolizumab in NSCLC: Enhancing Antitumor…Abstract4d ago4d ago